Drug Profile
Complement C1 inhibitor protein subcutaneous - Takeda
Alternative Names: Hyaluronidase/complement C1 inhibitor proteinLatest Information Update: 08 Dec 2021
Price :
$50
*
At a glance
- Originator ViroPharma
- Developer Halozyme Therapeutics
- Class Anti-ischaemics; Antianaemics; Complement C1 inactivator proteins; Eye disorder therapies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Complement C1 inhibitors; Enzyme modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hereditary angioedema
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 11 Mar 2014 ViroPharma is now called Shire ViroPharma
- 24 Jan 2014 ViroPharma has been acquired by Shire